This article was originally published in The Gray Sheet
Executive SummaryCirculatory support and vascular graft device maker plans secondary offering of 4.5 mil. shares of common stock, including 3 mil. shares offered by the company and 1.5 mil. shares sold by an existing shareholder. Lehman Brothers is lead underwriter for the offering, with co-managers Bear Stearns and Adams Harkness & Hill
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.